Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients

Clinical Infectious Diseases

Volumn 68, Issue 10, 2019, Pages 1641-1649

  Foolad, Farnaz ^a   Aitken, Samuel L ^a,b   Shigle, Terri Lynn ^a   Prayag, Amrita ^a   Ghantoji, Shashank ^a   Ariza Heredia, Ella ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Aerosolized ribavirin; Hematopoietic cell transplant; Oral ribavirin; Outcome; Respiratory syncytial virus

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADULT; AEROSOL; AGED; ALL CAUSE MORTALITY; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY RATE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; COMPARATIVE STUDY; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; MEDICAL RECORD; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; RISK FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85067607009     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy760     Document Type: Article

References (28)

1. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84.
2. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755-63.
3. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46:402-12.
4. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11:781-96.
5. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76:142-6.
6. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68:1872-80.
7. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56:258-66.
8. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209:1195-204.
9. Gorcea CM, Tholouli E, Turner A, et al. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients. J Hosp Infect 2017; 95:214-7.
10. Boeckh M, Englund J, Li Y, et al; NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245-9.
11. Casey J, Morris K, Narayana M, Nakagaki M, Kennedy GA. Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2013; 48:1558-61.
12. Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16:242-50.
13. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014; 123:3263-8.
14. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 2016; 18:634-6.
15. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016; 18:210-5.
16. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399-424.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
18. Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003; 26:172-81.
19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377-81.
20. Riner A, Chan-Tack KM, Murray JS. Original research: Intravenous ribavirin-review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review. Postgrad Med 2009; 121:139-46.
21. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 59(Suppl 5):S344-51.
22. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68:1872-80.
23. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19:589-96.
24. Gueller S, Duenzinger U, Wolf T, et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013; 15:435-40.
25. Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 2013; 48:1548-53.
26. K Gupta S, Kantesaria B, Glue P. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discov Ther 2014; 8:89-95.
27. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol 2012; 68:415-8.
28. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther 2013; 7:158-63.